NL-OMON26431招募中不适用
Imaging of ER density to guide and improve tailored therapy for acquired anti-hormonal resistant breast cancer.
niversity Medical Center Groningen (UMCG), department of medical oncology0 个研究点目标入组 50 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 50
研究概览
简要总结
- Dehdashti F, Mortimer JE, Trinkaus K. et al. PET-based estradiol challenge as a predictive biomarker of response to endocrine therapy in women with estrogen-receptor-positive breast cancer. Breast Cancer Res Treat (2009) 113:509-517;
2. Ellis MJ, Dehdashti F, Kommareddy A et al. A randomized phase 2 trial of low dose (mg daily) versus high dose (30mg daily) estradiol for patients with estrogen receptor positive aromatase inhibitor resistant advanced breast cancer. Breast Cancer Symposium 2008 San Antonio.
研究设计
- 研究类型
- Observational
入排标准
入选标准
- •1. Patients with the diagnosis of acquired anti-hormonal resistant advanced breast cancer showing progression after two or more lines of antihormonal treatment;
- •2. Treatment with estradiol will be started;
排除标准
- •1. Life Expectancy <3 months;
- •2. Uncontrolled CNS metastases;
研究者
相似试验
已完成
不适用
Imaging of ER Density to Guide and Improve Tailored Therapy for Acquired Anti-hormonal Resistant Breast CancerBreast CancerNCT01088477University Medical Center Groningen21
终止
不适用
[18F]FES PET/CT in PAHPulmonary Arterial HypertensionNCT02899533University of Pennsylvania5
已完成
2 期
Palbociclib and FES PETBreast CancerNCT02806050University Medical Center Groningen30
终止
2 期
[18F]FES PET/CT in Endocrine Refractory Breast CancerEstrogen Receptor Positive Breast CancerBreast NeoplasmMetastatic Breast CancerNCT02409316University of Pennsylvania6
招募中
4 期
Brain [18F]-FES PET/CT in Patients With Estrogen-Receptor Positive Breast CancerBrain MetastasesBreast CancerNCT06072807Weill Medical College of Cornell University20